STUDY OF LIPOPROTEIN PATTERNS AS AN ATHEROGENIC FACTOR IN T2DM PATIENTS AND THEIR FDRS

Authors

  • Gull Rukh
  • Nasir Ali
  • Naeema Afzal
  • Taher Salim Khan
  • S. Shahjahan

Abstract

Background: The present study was carried out to determine the lipoprotein patterns as anatherogenic factor in T2DM (Type 2 Diabetes Mellitus) patients and their FDRS (First DegreeRelatives). In various previous studies it has been reported that hyperinsulinemia andhyperlipidemia frequently coexist in T2DM patients which indicate that the diabetic state it self isassociated with atherogenic lipid disorders. Method: The present study included 26 Type 2DM(T2DM) patients and 21 apparently healthy First Degree Relative (FDRs) of T2DM patients.Twenty three age matched control not related to diabetics were also included in the study. Results:The BMI in male patients and FDRs were significantly higher as compared to controls but nosignificant difference was seen among the BMI of female FDRs. Fasting plasma glucose (FPG)levels of T2DM patients were significantly higher but no significant difference was observedamong the FDRs and controls. FPG did not show any significant correlation with the BMI indiabetic patients, FDRs and controls. The lipid profile of patients showed no significantdifference, except the mean LDL-Chol of female patients was significantly higher as compared tofemale controls. HDL-Chol of males FDRs was significantly lower as compared to male controls.LDL-Chol of female FDRs was significantly lower than the female controls. No significantdifference was observed in the total cholesterol and the triglycerides level of the patients of T2DMand FDRs but those cases in which pre-beta band appear upon lipoprotein electrophoresis hadsignificantly higher triglyceride levels as compared to those patients in which pre-beta band didnot appear. Conclusion: Lipoproteins of the T2DM patients and FDRs group were found to behighly disturbed as compared to the control group and they show a trend of developingatherogenic states in future.Key Words: Type 2 Diabetes Mellitus (T2DM), First Degree Relatives (FDRs), Body Mass Index(BMI), Lipoproteins, Fasting Plasma Glucose (FPG), Coronary Artery Disease

References

Jawaid SA, Jafary MH. Training of nurses in diabetic care.

Pak J Med Sci 2003;19(2):67–9.

Edelman SV. Type II diabetes mellitus. Adv-Intern-Med

;43:449–500.

Axelsen M. Smith U, Eriksson JW, Taskinen MR, Jansson

PA. Postprandial hypertriglyceridemia and insulin resistance

in normoglycemic first-degree relatives of patients with type

diabetes. Ann Intern Med 1999;131(1):27–31.

Al-Nuaim AR, Famuyiwa O, Geer W. Hyperlipidemia

among Saudi diabetic patients. Pattern and clinical

characteristics. Ann Saudi Med 1995;15(3):240–3.

Stewart MW, Humphriss DB, Mitcheson J, Webster J,

Walker M, Laker MF. Lipoprotein composition and serum

apolipoproteins in normoglycaemic first degree relatives of

non-insulin dependant diabetic patients. Atherosclerosis

;139(1):115–21.

Schlenck A, Herbeth B, Siest G, Visvikis S. Characterization

and quantification of serum lipoprotein subtractions by

capillary isotachophoresis: relationships with lipid,

apolipoproteins, and lipoprotein levels. Journal of Lipid

Research 1999;40:2125–33.

Mahley RW, Innerarity TL, Rall SC, Weisgraber KH. Plasma

lipoproteins: apolipoprotein structure and function. Journal of

Lipid Research 1984;25:1277–94.

Uddin F, Miah AK. Lipid profile and its relation to fasting insulin

level in non-insulin dependent diabetes mellitus (NIDDM).

Bangladesh Med Res Counc Bull 1995;21(2):64–72.

Fabryova L, Cagan S. Relation between insulin resistance

and small, dense lipoproteins with low density and the

development of atherosclerosis in type 2 diabetes mellitus.

Bratisl Lek Listy 1998;99(3-4):138–45.

Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH,

Jansen H. Atorvastatin dose-dependently decreases hepatic

lipase activity in type 2 diabetes: effect of sex and the LIPC

promoter variant. Diabetes Care 2003;26(2):427–32.

Hidaka H, Tozuka M, Meyer B, Yamauchi K, Sugono M,

Nakabayashi T, Katsuyama T. Characterization of triglyceride

rich lipoproteins with very light density by ultracentrifugation

and agarose gel electophoresis using triglyceride- and

cholesterol-staining. Ann Clin Lab Sci 2003;33(2):167–78.

Friedwald WT, Levy RI, Fredrickson DS. Clin Chem.

;18:499. Cited by Varley’s Practical Clinical

Biochemistry 1988; 6th ed, pp 462.

Stejskal D, Adamovska S, Bartek J, Jurakova R, Proskova J.

Resistin-concentrations in persons with type 2 diabetes

mellitus and in individuals with acute inflammatory disease.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

;147(1):63–9.

Perry IJ, Wannamethee SG, Walker MK, Thomson AG,

Whincup PH, Shaper AG. Prospective study of risk factors

for development of non-insulin dependent diabetes in middle

aged British men. BMJ 1995;310:560–4.

Chang SA, Kim HS, Yoon KH, Ko SH, Kwon HS, Kim et al.

Body mass index is the most important determining factor for

the degree of insulin resistance in non-obese type 2 diabetic

patients in Korea. Metabolism 2004;53(2):142–6.

Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight

gain as a risk factor for clinical diabetes mellitus in women.

Ann Interna Med. 122:481–6.

Habib SS, Aslam M. Risk Factors, knowledge and health status

in diabetic patients. Saudi Med J 2003;24(11):1219–24.

Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt

W, Kobberling J. A 25-year follow-up study of glucose

tolerance in first-degree relatives of type 2 diabetic patients:

association of impaired or diabetic glucose tolerance with

other components of the metabolic syndrome. Acta Diabetol

;40(4):163–72.

Cam H, Pusuroglu K, Aydin A, Ercan M. Effects of

hemorheological factors on the development of hypertension

in diabetic children. J Trop Pediatr 2003;49(3):164–7.

Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber

T, Owen TR. Comparison of the Effects of Three

Insulinotropic Drugs on Plasma Insulin Levels After a

Satandard Meal. Diabetes Care 2002;25,1271–6.

Woolf SH, Rothemich SF. New Diabetes Guidelines: A

Closer Look at the Evidence. American family physician

; 58:432-8.

Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD,

Blair SN. The Association between Cardiorespiratory Fitness

and Impaired Fasting Glucose and Type 2 Diabetes Mellitus

in Men. Ann of Inter Med 1999;130:89–96.

McClain MR . Modifiable Risk Factors For Diabetes

Detectable In Young Adults With Diabetic parents. Prev Med

;31:1–7.

Sanchez-Quesada JL, Perez A, Caixas A, Rigla M, Payes A,

Benitez S, Ordonez-Llanos J. Effect of Glycemic Optimization

on Electronegative Low–Density Lipoprotein in Diabetes:

Relation to Nonezymatic Glycosylation and Oxidative

Modification. J of Clin Endocrin & Met 2001;86:3243–9.

Parhofer KG, Laubach E, Geiss HC, Otto C. Effect of

glucose control on lipid levels in patients with type 2

diabetes. Dtsch Med Wochenschr 2002;127(18):958–62.

Laasko M, Pyorala K, Voutilainen E, Marniemi J. Plasma

insulin and serum lipids and lipoproteins in middle-aged sub

dependant diabetic and non-diabetic subjects. Ann J

Epidemiol 1987;125(4):611–21.

Demant T. Diabetic dyslipoproteinemia: physiophthological

bases and treatment prospects. Fosrtschr Med Orig

;119(1):37–40.

Petersen M, Pedersen H, Major–Pedersen A, Jensen T,

Marckmann P. Effect of Fish Oil Versus Com oil

Supplementation on LDL and HDL Subclasses in Type 2

Diabetic Patients. Diabetes Care 2002;25:1704–8.

Eschwege E. The dysmetabolic syndrome, insulin resistance

and increased cardiovascular (CV) morbidity and mortality in

J Ayub Med Coll Abbottabad;19(4)

type 2 diabetes: aetiological factors in the development of CV

complications. Diabetes Metab 2003;29(4 Pt 2):6S19–27.

Steinmetz A. Treatment of diabetic dyslipoproteinemia. Exp

Clin Endocrinol Diabetes 2003;111(5):239–45.

Gurlek A, Bayraktar M, Kirazli S. Increased plasminogen

activator inhibitor-1 activity in offspring of type 2 diabetic

patients. Diabetes Care 2000; 23:1035-7.

Ali N, Afzal N, Ahmad MZ, Shahjahan S, Shaikh AS.

Obesity indices and lipid levels in healthy relatives of T2DM

patients. Pak. PGMJ 2003;14(4):189–93.

Noble RP. Electrophoretic separation of plasma lipoproteins

in agarose gel. Journal of Lipid Research 1986;9:693–700.

Ravel R. In Clinical Laboratory Medicine, 3rd ed., Year Book

Medical publishers 1978: pp 251–7.

Tonutti L, Taboga C, Noacco C. Comparison of the efficacy

of pantethine, acipimox, and bezafibrate on plasma lipids and

index of cardiovascular risk in diabetics with dyslipidemia.

Minerva Med 1991;82:657–63.

Arsenio L, Bodria P, Magnati G, Pola P, Savi L, Girilli M.

Effectiveness of long-term treatment with pantethine in

patients with dyslipidemia. Clin Ther 1986;8:537–45.

Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas

JM, Jenner J, Myers RH et al. Familial lipoprotein disorders

in patients with premature coronary artery disease.

Circulation 1992;85:2025–33.

Durruty P, Diaz J, Zanetti L, de la Varas MA, Garcia de los

Rios M. Microalbuminuria, lipid changes and coronary heart

disease in non-insulin-dependent diabetics. Rev Med Chil

;126(12):1425–33.

Downloads

Most read articles by the same author(s)

1 2 > >>